Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 22 member 23 (SLC22A23)
- Target
- SLC22A23
- Molecular classification
- Transporter, Solute carrier (SLC) family
01
Overview
Solute carrier family 22 member 23 (SLC22A23) is a transmembrane protein belonging to the organic ion transporter family, specifically the solute carrier (SLC) superfamily. SLC22A23 is considered an orphan transporter, meaning its endogenous substrate(s) and exact functional role remain uncharacterized. Genome-wide association studies have linked variants in SLC22A23 to drug-induced QT interval prolongation and susceptibility to intestinal inflammation such as ulcerative colitis. Its expression in heart tissue and implication in cardiac development suggest a role in modulating cardiac electrophysiology by regulating the movement of bioactive molecules. SLC22A23 may also impact gastrointestinal inflammatory diseases by altering the bioavailability or clearance of metabolic substrates relevant to inflammation.
- Other names
- C6orf85FLJ221743110004L20RikDKFZP434F011Nritpsolute carrier family 22, member 23S22AN_HUMAN
02
Biological functions
Transport of organic ions across cell membranes (potentially includes drugs, environmental toxins, and endogenous metabolites)Cardiac electrophysiology modulation (inferred from cardiac expression and GWAS links to QT prolongation)Possible influence on intestinal inflammatory processes
03
Disease associations
Cardiac arrhythmias (e.g., drug-induced QT prolongation)Inflammatory bowel disease (e.g., ulcerative colitis)Intestinal inflammation
04
Safety considerations
Potential for involvement in drug-induced cardiac arrhythmia (QT prolongation), based on genetic association studies
05
Biomarkers
SLC22A23 gene variants (e.g., SNP rs17309827-T) have been associated with drug-induced QT prolongation and risk for ulcerative colitis
Beyond the preview
Go deeper on Solute carrier family 22 member 23 (SLC22A23).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solute carrier family 22 member 23 (SLC22A23).